Welcome to the e-CCO Library!

P486: Response to vedolizumab therapy in patients with inflammatory bowel disease: Impact of drug levels, anti-drug antibodies and α4β7 target occupancy
Year: 2018
Source: ECCO '18 Vienna
Authors:

B. Ungar1*, U. Kopylov1, M. Yavzori1, E. Fudim1, O. Picard1, A. Lahat1, D. Coscas1, M. Waterman2, O. Haj-Natour1, N. Orbach-Zingboim1, R. Mao3, M. Chen3, Y. Chowers4, R. Eliakim1, S. Ben-Horin1

Created: Thursday, 21 February 2019, 9:14 AM
P486: Treatment-emergent COVID-19 infections in ozanimod ulcerative colitis and multiple sclerosis clinical trials
Year: 2022
Source: ECCO'22
Authors: Ungaro , R.(1);Siegel , C.A.(2);Cree , B.A.C.(3);Selmaj , K.W.(4,6);Ahmad , H.A.(5);Pai , A.(5);Ather , S.(5);Henry , A.(5);Charles , L.(5);Petersen , A.(5);Cheng , C.Y.(5);Afsari , S.(5);Sheffield , J.(5);Vaile , J.(5);Colombel , J.F.(1);
Created: Friday, 11 February 2022, 3:56 PM
P487 Development and validation of a new patient-reported outcome measure for Crohn’s perianal fistula: Crohn’s anal fistula quality-of-life (CAF-QoL) scale
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Adegbola1, L. Dibley2, K. Sahnan1, P. Tozer1, T. Wade3, A. Verjee4, R. Sawyer4, S. Mannick4, D. McCluskey4, N. Yassin1, R. Phillips1, C. Norton3, A. Hart1

Created: Thursday, 30 January 2020, 10:12 AM
P487: Anti TNF induced psoariasiform skin eruptions are increasing in in the biosimilar era – a descriptive study of drug induced skin manifestations and their management
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Nu, K.P.(1)*;Stamp, K.(1);Shaji, S.(1);
Created: Friday, 14 July 2023, 11:05 AM
P487: Early vedolizumab trough levels are not associated with a short-term response in patients with inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

K. Pudilova1, M. Kolar1, D. Duricova*1, K. Malickova1,2, V. Hruba1, N. Machkova1, R. Vanickova1, K. Mitrova1, M. Lukas1, M. Vasatko1, M. Lukas1, M. Bortlik1,3,4

Created: Friday, 22 February 2019, 9:41 AM
P487: Effectiveness and safety of CT-P13 under routine care in paediatric patients with inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Choe Y.H.*1, Yang H.R.2, Moon J.S.3, Ryoo E.4, Kim S.5, Lee J.H.6, Kim H.J.7, Park J.H.8, Kim M.J.9, Lee S.J.10, Lee S.Y.10

Created: Wednesday, 20 February 2019, 10:36 AM
P487: Surgery due to inflammatory bowel disease during pregnancy: mothers and offspring outcomes (SCAR Study)
Year: 2022
Source: ECCO'22
Authors: Chaparro, M.(1);Aguas, M.(2);Livne, M.(3);Rivière, P.(4);Bar-Gil Shitrit, A.(5);Myrelid, P.(6);Arroyo, M.(7);Barreiro-de Acosta, M.(8);Bautista, M.(9);Biancone, L.(10);Biron, I.A.(5);Boysen, T.(11);Carpio, D.(12);Castro, B.(13);Dragoni, G.(14);Ellul, P.(15);Holubar, S.D.(16);de Jorge, M.Á.(17);Leo, E.(18);Manceñido, N.(19);Moens, A.(20);Ramírez de la Piscina, P.(21);Ricanek, P.(22);Sebkona, L.(23);Sempere, L.(24);Teich, N.(25);Gisbert, J.P.(1);Julsgaard, M.(26);
Created: Friday, 11 February 2022, 3:56 PM
P487: The effect of a coordinated care programme for inflammatory bowel diseases on health care utilisation
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

W. K. van Deen*1, M. Skup2, A. Centeno1, N. Duran1, P. Lacey1, D. Jatulis3, E. Esrailian1, M. G. van Oijen4, D.W. Hommes1

Created: Friday, 22 February 2019, 9:49 AM
P487: The feasibility of a digital platform for improving disease management among patients with Ulcerative Colitis
Year: 2021
Source: ECCO'21 Virtual
Authors: Oddsson, S.(1);Gunnarsdottir, T.(1);Ylanne, K.(2);Molander, P.(3);Thorgeirsson, T.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P487: Tofacitinib for the treatment of ulcerative colitis: Analysis of infection rates from the OCTAVE clinical programme
Year: 2018
Source: ECCO '18 Vienna
Authors:

K.L. Winthrop1, E.V. Loftus Jr.2, D.C. Baumgart3*, W. Reinisch4, A.J. Thorpe5, C.I. Nduaka5, N. Lawendy5, G. Chan5, R.D. Pedersen5, G.S. Friedman5, C. Su5

Created: Thursday, 21 February 2019, 9:14 AM
P488 How reliable is the online medical information on paediatric inflammatory bowel diseases?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Velasco Rodríguez-Belvís1, L.M. Palomino Pérez1, C. Sánchez Fernández-Bravo1, A. Sanchiz Perea2, L.F. Jose Luis1, G. Domínguez Ortega1, E. Cañedo Villarroya1, C.C. Pedrón Giner1, M.P. Jorge1, S. Rodríguez Manchón1, A. Muñoz González1, R.A. Muñoz Codoceo1

Created: Thursday, 30 January 2020, 10:12 AM
P488: Does Statin use reduce the risk of J-pouch related complications in patients with inflammatory bowel disease?
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kaimakliotis P., Lazarev M., Bayless T., Parian A., Brant S., Melia J., Truta B.

Created: Wednesday, 20 February 2019, 10:36 AM
P488: Efficacy of pre-operative oral antibiotic prophylaxis for the prevention of wound infections in patients with Crohn's disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Uchino*, H. Ikeuchi, T. Bando, T. Chohno, H. Sasaki, Y. Horio, R. Kuwahara, T. MInagawa

Created: Thursday, 21 February 2019, 9:14 AM
P488: IBS-type symptoms in patients with quiescent inflammatory bowel disease are unrelated to ongoing inflammation
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

D. Hoekman*1, J. Zeevenhooven2, G. D’Haens3, M. Benninga1

Created: Friday, 22 February 2019, 9:49 AM
P488: Perianal Crohn's disease in the biological era
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

F. Pires*1, A. Carvalho1, D. Martins1, E. Cancela1, A. Silva1, P. Ministro1

Created: Friday, 22 February 2019, 9:41 AM
P488: Switch from intravenous to subcutaneous infliximab in patients with Inflammatory Bowel Disease: efficacy, safety and patients' acceptance
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Caballol Oliva, B.(1)*;Fernàndez-Clotet, A.(2);Panés, J.(2);Masamunt, M.C.(2);Gallego, M.(2);Barastegui, R.(2);Vara, A.(2);Giner, À.(2);Ricart, E.(2);Ordás, I.(2);
Created: Friday, 14 July 2023, 11:05 AM
P488: The COVID19 pandemic impact on Inflammatory Bowel Disease Patients Management in a Romanian Tertiary Gastroenterology Centre
Year: 2021
Source: ECCO'21 Virtual
Authors: Costache, R.(1);Iacob, R.(1);Vadan, R.(1);Stroie, T.(1);Gheorghe, L.(1);Diculescu, M.(1);Gheorghe, C.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P488: Trends in corticosteroid (CS) use over time and following diagnosis in patients with Inflammatory Bowel Disease (IBD), using IBM® MarketScan®
Year: 2022
Source: ECCO'22
Authors: Raine, T.(1);Melmed, G.Y.(2);Finney-Hayward , T.(3);Clark, R.(4);Chapman, J.C.(5);Targownik, L.(6);Burisch, J.(7);Olen, O.(8);
Created: Friday, 11 February 2022, 3:56 PM
P489 Are patients with inflammatory bowel disease receiving an adequate immunisation?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

D. Simian1, P. Núñez2, L. Flores1, C. Figueroa1, P. Ibáñez1, U. Kronberg1, J. Lubascher1, G. Pizarro1, R. Quera1

Created: Thursday, 30 January 2020, 10:12 AM
P489: Clinical experience with ustekinumab in selected Crohn's disease patients
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Saman*, T. Klag, J. Wendler, M. Goetz, N.P. Malek, J. Wehkamp

Created: Thursday, 21 February 2019, 9:14 AM